X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Telix Pharmaceuticals have access to lead investigational drug Cycloslam (samarium-153-DOTMP) for the treatment of therapeutic radiopharmaceuticals for primary and metastatic bone cancer.
Lead Product(s): Samarium-153-DOTMP
Therapeutic Area: Oncology Product Name: CycloSam
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: QSAM Biosciences
Deal Size: $123.1 million Upfront Cash: $33.1 million
Deal Type: Acquisition February 07, 2024
Details:
TLX250-CDx (89Zr-DFO-girentuximab) PET/CT imaging has the potential to improve patient care by serving as a “molecular biopsy” that could be used to guide surveillance, further imaging, or biopsy across all stages of disease.
Lead Product(s): 89Zr-DFO-girentuximab
Therapeutic Area: Oncology Product Name: TLX250-CDx
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
TLX250-CDx (89Zr-DFO-girentuximab) is a large molecule drug candidate, which is currently being evaluated for the treatment of clear cell renal cell carcinoma via intravenous infusion.
Lead Product(s): 89Zr-DFO-girentuximab
Therapeutic Area: Oncology Product Name: TLX250-CDx
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2023
Details:
Through the acquisition, Telix gain rights to CycloSam (samarium-153-DOTMP), a novel, de-risked clinical asset that has the potential to deliver tangible improvements of prior bone-seeking agents.
Lead Product(s): Samarium-153-DOTMP
Therapeutic Area: Oncology Product Name: CycloSam
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: QSAM Biosciences
Deal Size: $125.1 million Upfront Cash: $2.0 million
Deal Type: Acquisition November 13, 2023
Details:
TLX591 (177Lu-DOTA-TLX591) is first-in-class radio-antibody drug conjugate (rADC) investigational therapy, which is investigated for the the treatment of prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer.
Lead Product(s): Lutetium-177 Rosopatamab Tetraxetan
Therapeutic Area: Oncology Product Name: TLX591
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
Details:
TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) is one of Telix's lead therapeutic clinical programs and has been granted orphan drug designation in the United States and Europe for glioblastoma therapy.
Lead Product(s): [131I]Iodo-phenylalanine,Temozolomide
Therapeutic Area: Oncology Product Name: TLX101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2023
Details:
Under the agreement, Telix will suppy Illuccix (TLX591-CDx, kit for the preparation of gallium Ga 68 gozetotide injection) for the Phase III ARASTEP study, investigating Bayer's ARi Nubeqa (darolutamide) plus ADT versus ADT alone in hormone-sensitive prostate cancer.
Lead Product(s): Darolutamide,Androgen Deprivation Therapy
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Bayer AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 08, 2023
Details:
LY3012207 (olaratumab) is a mAb targeting PDGFRα. It was granted accelerated approval in the U.S. and conditional approval in the EU based on Phase II trial data which showed a 1-year survival benefit in patients with STS, when given in combination with standard chemotherapy.
Lead Product(s): Olaratumab,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: LY3012207
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
Illuccix (gallium Ga 68 gozetotide) binds to PSMA. It binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. Gallium 68 (Ga 68) is a β+ emitting radionuclide that allows positron emission tomography.
Lead Product(s): Gallium Ga 68 Gozetotide
Therapeutic Area: Oncology Product Name: Illuccix
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Details:
TLX250-CDx (89Zr-DFO-girentuximab) PET/CT imaging has the potential to improve patient care by serving as a “molecular biopsy” that could be used to guide surveillance, further imaging, or biopsy across all stages of disease.
Lead Product(s): 89Zr-DFO-girentuximab
Therapeutic Area: Oncology Product Name: TLX250-CDx
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
